Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions
- PMID: 10589746
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions
Abstract
Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis and vascular permeability. We hypothesized that malignant pleural effusions may contain high levels of VEGF protein as well as other cytokines implicated in these processes. Pleural effusions cytologically proven to be malignant were collected from 39 patients with various types of cancer, and VEGF, interleukin-8, and angiogenin levels in the effusions were determined by immunoassay. Negative controls were nonmalignant ascites and serum samples from healthy individuals. VEGF levels were significantly higher than those of control samples in pleural effusions secondary to breast, mesothelioma, and non-small cell lung cancer and when all malignant pleural effusion samples were pooled. Neither interleukin-8 nor angiogenin levels were elevated in malignant pleural effusions relative to the control samples. Vascular permeability, which was measured by using the Miles assay in nude mice, was increased proportionately with VEGF levels in the malignant pleural effusions; this increase in permeability induced by injection of recombinant VEGF or the malignant effusions was reduced by pretreating the mice with a VEGF receptor antibody.
Similar articles
-
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.Clin Cancer Res. 2000 Mar;6(3):957-65. Clin Cancer Res. 2000. PMID: 10741721
-
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.J Pathol. 2001 Apr;193(4):468-75. doi: 10.1002/path.824. J Pathol. 2001. PMID: 11276005
-
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.Cancer. 1999 Jan 1;85(1):178-87. Cancer. 1999. PMID: 9921991
-
Vascular endothelial growth factor (VEGF) and its effect on angiogenesis.Med Sci Monit. 2000 Sep-Oct;6(5):1047-52. Med Sci Monit. 2000. PMID: 11208453 Review.
-
Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas.Leuk Lymphoma. 2001 Apr;41(3-4):229-37. doi: 10.3109/10428190109057978. Leuk Lymphoma. 2001. PMID: 11378536 Review.
Cited by
-
Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo.J Cell Mol Med. 2022 Nov;26(22):5580-5589. doi: 10.1111/jcmm.17570. Epub 2022 Oct 9. J Cell Mol Med. 2022. PMID: 36209502 Free PMC article.
-
Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.Exp Ther Med. 2012 Jun;3(6):1072-1076. doi: 10.3892/etm.2012.514. Epub 2012 Mar 14. Exp Ther Med. 2012. PMID: 22970019 Free PMC article.
-
[Therapeutical effects of pleural injecting recombinant human endostain to malignant pleural effusion nude mice model].Zhongguo Fei Ai Za Zhi. 2015 May;18(5):266-71. doi: 10.3779/j.issn.1009-3419.2015.05.03. Zhongguo Fei Ai Za Zhi. 2015. PMID: 25975296 Free PMC article. Chinese.
-
A pilot study of long-acting octreotide for symptomatic malignant ascites.Oncology. 2012;82(6):315-20. doi: 10.1159/000337246. Epub 2012 May 10. Oncology. 2012. PMID: 22572824 Free PMC article. Clinical Trial.
-
Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array.Proteome Sci. 2014 May 13;12:27. doi: 10.1186/1477-5956-12-27. eCollection 2014. Proteome Sci. 2014. PMID: 24883046 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical